We first observed that FATP5 was expressed at low levels in both HCC and tumor thrombus tissues, and decreased expression of FATP5 was positively associated with more invasive clinicopathological features and a worse prognosis in HCC patients, suggesting an anti-oncogenic role of FATP5 as a tumor suppressor in HCC progression. The gene discussed is SLC27A5; the disease is hepatocellular carcinoma.